Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Forum on Immunopathological Diseases and Therapeutics
SJR: 0.309 SNIP: 0.041 CiteScore™: 0.18

ISSN Imprimer: 2151-8017
ISSN En ligne: 2151-8025

Archives: Volume 1, 2010 to Volume 7, 2016

Forum on Immunopathological Diseases and Therapeutics

DOI: 10.1615/ForumImmunDisTher.2016017273
pages 119-126

KLF4 in Ovarian Cancer

Junming Yue
Department of Pathology and Laboratory Medicine and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38163
Baojin Wang
The Third Affiliated Hospital, Zhengzhou University, China
Ziyun Du
Department of Pathology and Laboratory Medicine and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38163
Lawrence M. Pfeffer
Department of Pathology and Laboratory Medicine and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38163

RÉSUMÉ

The Kruppel-like factor 4 (KLF4) transcriptional factor functions as a tumor suppressor or oncogene in different human cancers. Ovarian cancer is one of the most aggressive malignancies in women. In this review, we discuss the role of KLF4 and the KLF4 regulatory network in ovarian cancer. KLF4 expression inhibits ovarian cancer cell proliferation, migration, invasion, and metastasis. KLF4 inhibits the epithelial-to-mesenchymal transition by directly binding to the promoter of E-cadherin in ovarian cancer cells. Moreover, KLF4 inhibits the cancer stem cell phenotype in ovarian cancer. KLF4 not only regulates microRNA expression but is also targeted by microRNAs. It is a potential biomarker for prognosis and drug targeting in ovarian cancer and may contribute to ovarian cancer metastasis and chemoresistance through a complex gene regulatory network.

MOTS CLÉS: EMT, KLF4, ovarian cancer